<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: oa--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11875707</article-id><article-id pub-id-type="pmc">2375223</article-id><article-id pub-id-type="pii">6600072</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6600072</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular and Cellular Pathology</subject></subj-group></article-categories><title-group><article-title>Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Michalides</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van Tinteren</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Balkenende</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vermorken</surname><given-names>J B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Benraadt</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Huldij</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>van Diest</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Division of Tumour Biology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands</aff><aff id="aff2"><label>2</label>Department of Biometrics, the Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands</aff><aff id="aff3"><label>3</label>Department of Medical Oncology, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium</aff><aff id="aff4"><label>4</label>Comprehensive Cancer Center Amsterdam, Plesmanlaan 125, 1066CX Amsterdam, The Netherlands</aff><aff id="aff5"><label>5</label>Department of Pathology, VU Medical Center, PO Box 7057, NL-1007 MB Amsterdam, The Netherlands</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:rmichal@nki.nl.">rmichal@nki.nl</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>02</month><year>2002</year></pub-date><volume>86</volume><issue>3</issue><fpage>402</fpage><lpage>408</lpage><history><date date-type="received"><day>07</day><month>08</month><year>2001</year></date><date date-type="rev-recd"><day>05</day><month>11</month><year>2001</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2001</year></date></history><copyright-statement>Copyright 2002, The Cancer Research Campaign</copyright-statement><copyright-year>2002</copyright-year><permissions><copyright-holder>The Cancer Research Campaign</copyright-holder></permissions><abstract><p>Overexpression of G1-S regulators cyclin D1 or cyclin A is frequently observed in breast cancer and is also to result in ligand-independent activation of oestrogen receptor <italic>in vitro</italic>. This might therefore, provide a mechanism for failure of tamoxifen treatment. We examined by immunohistochemical staining the effect of deregulation of these, and other cell cycle regulators on tamoxifen treatment in a group of 394 patients with early stage breast cancer. In univariate analysis, expression of cyclin A, Neu, Ki-67 index, and lack of OR expression were significantly associated with worse prognosis. When adjusted by the clinical model (for lymph node status, age, performance status, T-classification, grade, prior surgery, oestrogen receptor status and tamoxifen use), only overexpression of cyclin A and Neu were significantly associated with worse prognosis with hazard ratios of, respectively, 1.709 (<italic>P</italic>&#x0003d;0.0195) and 1.884 (<italic>P</italic>&#x0003d;0.0151). Overexpression of cyclin A was found in 86 out of the 201 OR-positive cases treated with tamoxifen, and was the only independent marker associated with worse prognosis (hazard ratio 2.024, <italic>P</italic>&#x0003d;0.0462). In conclusion, cyclin A is an independent predictor of recurrence of early stage breast cancer and is as such a marker for response in patients treated with tamoxifen.</p><p><italic>British Journal of Cancer</italic> (2002) <bold>86</bold>, 402&#x02013;408. DOI: <ext-link ext-link-type="doi" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1038/sj/bjc/6600072">10.1038/sj/bjc/6600072</ext-link> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.bjcancer.com">www.bjcancer.com</ext-link></p><p>&#x000a9; 2002 <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.crc.org.uk">The Cancer Research Campaign</ext-link></p></abstract><kwd-group><kwd>cyclin A</kwd><kwd>cyclin D1</kwd><kwd>human breast cancer</kwd><kwd>prognosis</kwd><kwd>tamoxifen</kwd><kwd>cell cycle markers</kwd></kwd-group></article-meta></front><body><sec><title/><p>The signalling pathway of oestrogen receptor-&#x003b1;, OR-&#x003b1;, is a major determinant in human breast tumorigenesis (<xref ref-type="other" rid="bib7">Brown <italic>et al</italic>, 1999</xref>). This assumption is derived from observations that OR-&#x003b1; is only present in a minority of normal breast epithelial cells, whereas &#x0003e;70&#x00025; of human breast cancer contain OR-&#x003b1; (<xref ref-type="other" rid="bib36">Ricketts, 1991</xref>). Moreover, oestrogen causes proliferation of OR positive breast cancer cells (<xref ref-type="other" rid="bib11">Chalbos <italic>et al</italic>, 1982</xref>). The mitogenic activity of oestrogen is still far from being fully understood. Oestrogen induces rapid changes in cell cycle progression kinetics and results in altered expression of cell cycle markers in oestrogen responsive cells (<xref ref-type="other" rid="bib29">Musgrove <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib1">Altucci <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib18">Foster and Wimalasena, 1996</xref>). These involve key transitions in the eukaryotic cellular division, which are controlled by the sequential activation and inactivation of cyclin dependent protein kinases (cdk). The activity of these kinases is regulated by phosphorylation/dephosphorylation, subcellular traffic mechanism, association with cyclin proteins and with specific cdk-inhibitors, and by proteolytic degradation (<xref ref-type="other" rid="bib40">Sherr and Roberts, 1999</xref>). Of these cyclin-cdk complexes, cyclin D-cdk4/6 activity drives cells through the early G1 phase of the cell cycle, whereas cyclin E-cdk2 and subsequently cyclin A-cdk2 activities are required for transition through the later G1 phase of the cell cycle past the restriction point up to which growth factor stimulation is mandatory. The mitogenic activity of oestrogen involves stimulation of expression of cyclin D1 (<xref ref-type="other" rid="bib1">Altucci <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib39">Sabbah <italic>et al</italic>, 1999</xref>) and of cdc25A (<xref ref-type="other" rid="bib19">Foster <italic>et al</italic>, 2001</xref>) an activating phosphatase of cdk2 (<xref ref-type="other" rid="bib23">Jinno <italic>et al</italic>, 1994</xref>). Inhibition of oestrogen receptor activity by anti-oestrogens leads to reduced cyclin D1 expression and, as a consequence thereof, to a release of cdk-inhibitors p21 and p27 from the cyclin D-cdk4/6 complex that then become associated with cyclin-cdk2 complexes. This shift of cdk-inhibitors results in a cell cycle block in mid-G1 (<xref ref-type="other" rid="bib33">Planas-Silva and Weinberg, 1997</xref>; <xref ref-type="other" rid="bib34">Prall <italic>et al</italic>, 1997</xref>). A direct effect of anti-oestrogens on effectors of the cell cycle downstream of cyclin D1 can, however, not be excluded (<xref ref-type="other" rid="bib12">Cicatiello <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib19">Foster <italic>et al</italic>, 2001</xref>).</p><p>Anti-oestrogens compete with oestrogen for binding to the OR, but fail to induce receptor activation. These molecules interfere with multiple steps in the OR signalling pathway, including dissociation from chaperone proteins, nuclear translocation, dimerization and targeting to OR specific DNA elements and binding to transcriptional co-regulators (<xref ref-type="other" rid="bib31">Osborne <italic>et al</italic>, 2000</xref>). Because of their ability to disrupt OR signalling pathways, anti-oestrogens are widely used for the treatment of hormone-dependent breast cancer. The non-steroidal triphenyl-ethylene anti-oestrogen tamoxifen has been established as the first choice for adjuvant therapy of oestrogen-receptor positive breast cancer (<xref ref-type="other" rid="bib15">Early Breast Cancer Trialist's Collaborative Group, 1998</xref>; <xref ref-type="other" rid="bib48">Yao and Jordan, 1999</xref>).</p><p>OR-&#x003b1; signalling activity is not only induced by oestrogen, but OR-&#x003b1; is also activated as a transcriptional transactivator in a hormone-independent manner by phosphorylation of serines 104/106 by cyclin A-cdk2 (<xref ref-type="other" rid="bib38">Rogatsky <italic>et al</italic>, 1999</xref>) and by direct binding of OR-&#x003b1; to cyclin D1 (<xref ref-type="other" rid="bib49">Zwijsen <italic>et al</italic>, 1997</xref>). Both of these modulations affect the association between OR-&#x003b1; and co-activators of OR-&#x003b1; (<xref ref-type="other" rid="bib38">Rogatsky <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib50">Zwijsen <italic>et al</italic>, 1999</xref>) and may thereby affect the ability of anti-oestrogens to inhibit OR-&#x003b1; activity. It has, therefore, been hypothesized that tamoxifen treatment of breast cancer may be inefficient in tumour cases that harbour genetic lesions which result in elevated levels of cyclin D1 or A, or that lead to reduced levels of cdk inhibitors p21 or p27 (<xref ref-type="other" rid="bib28">Michalides, 1999</xref>; <xref ref-type="other" rid="bib10">Cariou <italic>et al</italic>, 2000</xref>). We have addressed this hypothesis by examining the effect of an altered expression of these cell cycle regulators on the outcome of tamoxifen treatment of patients with early stage of breast cancer.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patients and tumour specimens</title><p>The marker group of 394 patients is part of a clinical Comprehensive Cancer Center Amsterdam (IKA) Tamoxifen study on the effect of adjuvant tamoxifen treatment in breast cancer. Between 1982 and 1994, 1662 patients were randomized in a 2&#x0200a;:&#x0200a;1 distribution to control or tamoxifen (30&#x02009;mg day<sup>&#x02212;1</sup>). Patients were eligible if they were post-menopausal, less than 76 years of age and had a T<sub>1&#x02013;4</sub>, N<sub>0&#x02013;3,</sub> M<sub>0</sub> breast tumour (<xref ref-type="other" rid="bib47">World Health Organization, 1981</xref>), but no mastitis or palpable supra- or infraclavicular lymph nodes. Randomization was stratified by institute and nodal status (N&#x0002b;/N&#x02212;). After 1989, based on two interim analyses showing a significant improvement in progression-free survival in node positive patients, these patients skipped the first randomization and all received 1 year of tamoxifen. After 1 year they were again eligible for the second randomization in the study to receive either another 2 years of tamoxifen or to stop further treatment (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Design of the IKA Tamoxifen study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="86-6600072f1"/></fig>). The patient characteristics and clinical outcome of tamoxifen treatment of the original study group (1662 patients) have been presented elsewhere (<xref ref-type="other" rid="bib45">Vermorken <italic>et al</italic>, 1998</xref>). Of the patients in this trial, paraffin embedded material was available from a randomly sampled group of 394 patients. Tissues had been fixed for at least 24&#x02009;h in neutral buffered 4&#x00025; formaldehyde. After paraffin embedding, 4-&#x003bc;<sc>M</sc>-thick sections were cut and attached on silane-coated slides. All tumours used in the marker study were examined by one pathologist (PvD), were classified according to WHO criteria (<xref ref-type="other" rid="bib47">World Health Organization, 1981</xref>) and were graded according to a modification of Bloom and Richardson's method (<xref ref-type="other" rid="bib16">Elston and Ellis, 1990</xref>). During the clinical study, oestrogen receptor status was determined routinely by the dextran-coated charcoal assay on tumour cytosols. Receptor levels of &#x0003e;10&#x02009;fmol&#x02009;mg<sup>&#x02212;1</sup> of cytosolic protein were considered positive. Tumours were also examined for oestrogen receptor by immunohistochemistry.</p></sec><sec><title>Immunohistochemistry</title><p>Immunohistochemistry was performed as described previously (<xref ref-type="other" rid="bib27">Michalides <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib44">Van Diest <italic>et al</italic>, 1997</xref>). In all cases, except for staining with anti-Neu, antigen retrieval was applied by microwave treatment in citrate buffer pH&#x02009;6. Slides were blocked with 10&#x00025; normal serum, depending on the first antiserum to be used, and were incubated overnight with the following antisera and dilutions: from Novacastra (Newcastle, UK): cyclin D1 (clone DCS-6, 1&#x0200a;:&#x0200a;40); cyclin A (clone 6E6, 1&#x0200a;:&#x0200a;200), epidermal growth factor receptor, EGF-R (clone EGFR.113, 1&#x0200a;:&#x0200a;20); from Pharmingen (San Diego, USA): p21 (clone 6B6, 1&#x0200a;:&#x0200a;500); from Transduction Laboratories (Lexington, USA): p27 (clone K2052, 1&#x0200a;:&#x0200a;200); from Dako (Glostrup, Denmark): OR (clone OR1D7, 1&#x0200a;:&#x0200a;50), progesterone receptor, PgR (cl PgR 636, 1&#x0200a;:&#x0200a;100), p53 (clone DO-7, 1&#x0200a;:&#x0200a;500); from Immunotech SA (Marseille, France): Ki-67 (Mib1, 1&#x0200a;:&#x0200a;40). Anti-Neu antibody was obtained from M vd Vijver (The Netherlands Cancer Institute, Amsterdam, The Netherlands) and was used at a dilution of 1&#x0200a;:&#x0200a;1000. All first antibodies were incubated overnight at 4&#x000b0;C, except for anti-EGFR that was incubated at room temperature.</p><p>Biotinylated second antibodies (Dako, Glostrup, Denmark) were applied for 30&#x02009;min at room temperature, after which peroxidase-conjugated streptavidin-biotin labelling and subsequent DMBA staining was performed.</p><p>The slides were independently examined by two observers (PvD and RM). For staining of EGFR and Neu only, membrane staining was considered as positive staining. With the other markers, cells were considered to be positive only when distinct nuclear staining was identified. The percentage of immunoreactive cells was evaluated by scanning whole sections at medium and high magnifications. p27 expression was scored as low (&#x0003c;50&#x00025; reacting cells) and high (&#x0003e;50&#x00025;). Scores for positivity for cyclins D1 and E, OR, PgR, Ki-67, p21 and p53 were determined semi-quantitatively as described in Materials and Methods. The threshold for positivity for cyclin A staining was determined from analyzing the Martingale residuals of cyclin A positives with recurrence as the outcome. Above 5&#x00025;, which was also the median value of cyclin A, excess in risk for recurrence was observed. The range of cyclin A positive cells in this series ranged from 0&#x02013;50&#x00025;, with an average of 9.5&#x00025;. Cyclin D1, OR, PgR and Ki-67 were considered positive if &#x0003e;5&#x00025; of the cells stained, for cyclin A expression &#x0003e;10&#x00025; of the cells staining was considered as positive. All cases expressing cyclin E, p21 and p53 were considered positive, this in accordance with earlier settings of (<xref ref-type="other" rid="bib27">Michalides <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib44">Van Diest <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib4">Barbareschi <italic>et al</italic>, 2000</xref>).</p></sec><sec><title>Statistical analysis</title><p>The endpoint for analysis was recurrence, defined as the first reappearance of breast cancer at any site (local, contralateral, or distant). Survival estimates and curves were calculated with the Kaplan-Meier technique and differences in time to recurrence were tested by means of a log-rank test. To estimate the association of markers with time to recurrence adjusted for other (known) clinically important variables, Cox proportional hazard analysis was used. The model for adjustment consisted of the following variables: lymph node status (N0, N&#x0002b;), Age (continuous), Karnofski performance index (&#x0003c;80, 80&#x02013;100), T-classification (T1, T2, T3, T unknown), histological grade (grade I, grade II, grade III), OR status (OR&#x0002b;, OR-, OR unknown), and breast conserving surgery or mastectomy. The association between each of the clinicopathological markers individually was analyzed by Spearman rank correlation.</p></sec></sec><sec><title>RESULTS</title><p>Baseline characteristics of the IKA tamoxifen trial patients who also participated in the marker study are shown in <xref rid="tbl1" ref-type="table">Table 1</xref><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Patient and tumour characteristics of the sample study of 394 patients</title></caption></table-wrap>. The median follow-up is almost 10 years in the tamoxifen study and over 8 years in the marker study. In 108 patients of the 394 patients in the marker study (27&#x00025;), breast cancer reappeared. The associations between clinical and pathological parameters and recurrence were as to be expected. The great majority of the 394 patients (320; 81&#x00025;) had received tamoxifen. Tamoxifen showed to be significantly associated with a better prognosis in the original trial group of 1662 patients (hazard ratio (HR)&#x0003d;0.66, 95&#x00025; CI 0.55&#x02013;0.80, <italic>P</italic>&#x0003d;0.0001), but a similar effect seen in the marker study group of 394 patients was not significant (HR&#x0003d;0.66, 95&#x00025; CI 0.39&#x02013;1.13, <italic>P</italic>&#x0003d;0.127).</p><p>The results of the marker studies and their association with time to recurrence are presented in <xref rid="tbl2" ref-type="table">Tables 2</xref><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Markers: frequency, 5-year survival estimates and log-rank test</title></caption></table-wrap> and <xref rid="tbl3" ref-type="table">3</xref><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Markers: HR and 95% CI, univariate and adjusted</title></caption></table-wrap>. Nuclear staining was also observed together with a weak positive cytoplasmic staining in some of the cyclin A positive tumour cells. This may well indicate cells at G2 phase of the cell cycle. In univariate analysis, expression of cyclin A and Neu, high Ki-67 index, and lack of OR expression were significantly associated with worse prognosis. When adjusted by the clinical model (for lymph node status, age, performance status, T-classification, grade, prior surgery, oestrogen receptor status and tamoxifen use), only overexpression of cyclin A and Neu were significantly associated with worse prognosis with HR of, respectively, 1.709 (<italic>P</italic>&#x0003d;0.0195) and 1.884 (<italic>P</italic>&#x0003d;0.0151), see also <xref ref-type="fig" rid="fig2">Figure 2</xref><fig id="fig2"><label>Figure 2</label><caption><p>Recurrence-free interval curves for groups of breast cancer patients (<bold>A</bold>) with and without overexpression of cyclin A, and (<bold>B</bold>) OR-positive breast cancer treated with tamoxifen, with and without overexpression of cyclin A (log rank <italic>P</italic> value&#x0003d;0.0462).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="86-6600072f2"/></fig>. None of the other markers used were independent indicators of prognosis, including cyclin D1, cyclin E, p53, p21, p27, and EGF-R.</p><p><xref rid="tbl4" ref-type="table">Table 4</xref><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Association between cyclin A overexpression and other cell cycle and related clinical markers in the markers study of 394 breast cancer patients</title></caption></table-wrap> summarizes the relationship between cyclin A expression and the other markers.</p><p>Cyclin A overexpression was significantly associated with overexpression of Neu, Ki-67, with expression of p53, with absence of OR, with high histological grade and high T-classification. Altogether, these associations suggest that overexpression of cyclin A is more frequently found in large size, undifferentiated, OR-negative breast tumours with an increased proliferative fraction. A representative cyclin A staining in breast cancer cells is given in <xref ref-type="fig" rid="fig3">Figure 3</xref><fig id="fig3"><label>Figure 3</label><caption><p>(<bold>A</bold>, <bold>B</bold>) Immunohistochemical staining of breast cancer with antibody 6E6 specific for cyclin A. Note the nuclear staining with a weak cytoplasmic staining in some of the cyclin A positive tumour cells that may indicate cells at G2 phase of the cell cycle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="86-6600072f3"/></fig>.</p><p>To analyze which of the markers studied contributed to a more inefficient treatment with tamoxifen, we examined a more restricted group of OR positive breast cancer patients treated with tamoxifen, presuming that any effect should be eminent here. Overexpression of cyclin A was the only independent marker associated with a worse prognosis in tamoxifen treated OR-positive tumours, with a HR of 2.024 (<italic>P</italic>&#x0003d;0.0462). Cyclin A overexpression was found in 86 out of 201 OR-positive cases that were treated with tamoxifen.</p></sec><sec><title>DISCUSSION</title><p>Cyclin D1 and cdc25A behave as oestrogen-sensitive oncogenes (<xref ref-type="other" rid="bib1">Altucci <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib39">Sabbah <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib19">Foster <italic>et al</italic>, 2001</xref>). Introduction of these genes in murine fibroblasts contributes to cellular transformation, and genetic alterations leading to increased expression of these genes are frequently observed in breast cancer (<xref ref-type="other" rid="bib35">Quelle <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib20">Galaktionov <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib28">Michalides, 1999</xref>; <xref ref-type="other" rid="bib9">Cangi <italic>et al</italic>, 2000</xref>). Mice transgenic for cyclin D1 are prone to tumour development, the type of tumour being dependent on the enhancer sequence used to construct the cyclin D1 transgene (<xref ref-type="other" rid="bib6">Bodrug <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib46">Wang <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib37">Robles <italic>et al</italic>, 1996</xref>). However, neither overexpression of cyclin D1 or of cdc25A was found to be an independent indicator of prognosis in early stage breast cancer (<xref ref-type="other" rid="bib27">Michalides <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib44">Van Diest <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib9">Cangi <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib26">Leong <italic>et al</italic>, 2000</xref>). The present study also indicates that overexpression of cyclin D1 does not affect the outcome of tamoxifen treatment of early stage, OR-&#x003b1; positive breast cancer. Although we did not study directly expression of cdc25A in these tumours, we found that overexpression of cyclin A is significantly associated with worse outcome in tamoxifen treated patients (<italic>P</italic>&#x0003d;0.0462). In the whole group of patients, including 247 OR-positive, 139 OR-negative and eight OR-unknown cases, overexpression of cyclin A and of Neu were indicative of worse outcome, with <italic>P</italic> values of 0.0195 and 0.0151 respectively (<xref rid="tbl3" ref-type="table">Table 3</xref>). Neu overexpression already has previously been reported to be associated with a worse prognosis (<xref ref-type="other" rid="bib41">Slamon <italic>et al</italic>, 1987</xref>) and more recently was found to be indicative of tamoxifen resistance (<xref ref-type="other" rid="bib22">Houston <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib42">Stal <italic>et al</italic>, 2000</xref>). The prognostic value of cyclin A overexpression may well be contributed to its interaction with large sized, undifferentiated, OR-negative breast tumours with an increased proliferative capacity (<xref rid="tbl4" ref-type="table">Table 4</xref>). However, also in the group of OR-&#x003b1;-positive breast cancers, cyclin A overexpression did behave as an independent marker of worse prognosis. In our study, overexpression of p53, indicative of p53 mutation, was not associated with outcome of disease or tamoxifen treatment. Only specific p53 mutations, determined by sequencing of the p53 gene, are most informative in predicting response to systemic therapy of advanced breast cancer (<xref ref-type="other" rid="bib2">Berns <italic>et al</italic>, 2000</xref>), whereas we examined early stage breast cancer by p53 immunohistochemistry, which is less accurate in detecting mutations.</p><p>We hypothesized that cyclin D1 and/or cyclin A might affect outcome of tamoxifen treatment, since both cyclins are hormone-independent activators of OR-&#x003b1; in <italic>in vitro</italic> experiments (<xref ref-type="other" rid="bib49">Zwijsen <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib38">Rogatsky <italic>et al</italic>, 1999</xref>). Cyclin D1 does so by binding to OR-&#x003b1; and thereby enhances the interaction between OR-&#x003b1; and SRC (steroid receptor coactivator)-1 (<xref ref-type="other" rid="bib50">Zwijsen <italic>et al</italic>, 1999</xref>), whereas cyclin A-cdk2 phosphorylates cdk2 at serines 104/106 (<xref ref-type="other" rid="bib38">Rogatsky <italic>et al</italic>, 1999</xref>), and thereby activates OR-&#x003b1; transcriptional activity. The activation of OR-&#x003b1; by these cyclins is tamoxifen-insensitive, but this depended on <italic>in vitro</italic> transient transfection where excess cyclin proteins are being generated. However, an experimentally induced six-fold overexpression of cyclin D1 in MCF-7 cells did not render these cells to grow in the presence of anti-oestrogens (<xref ref-type="other" rid="bib32">Pacilio <italic>et al</italic>, 1998</xref>). That finding and the present study indicate that overexpression of cyclin D1 as it is being observed under experimental <italic>in vitro</italic> transfection conditions, is not likely to be encountered <italic>in vivo</italic>. This may only be achieved during lactation where co-stimulation of protein kinase A together with oestrogens does result in excessive levels of cyclin D1 that activate OR (<xref ref-type="other" rid="bib25">Lamb <italic>et al</italic>, 2000</xref>). It should also be mentioned that cyclin D1 is stimulating OR transcriptional activity only when it is free of its regular cdk4/6 partner (<xref ref-type="other" rid="bib49">Zwijsen <italic>et al</italic>, 1997</xref>), but that free cyclin D1 is more prone to proteolytic degradation than when bound to cdk4/6 (<xref ref-type="other" rid="bib14">Diehl <italic>et al</italic>, 1997</xref>). Another confounding factor may be the activation by cyclin D1 of p21 (<xref ref-type="other" rid="bib3">Barbareschi <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib13">De Jong <italic>et al</italic>, 1999</xref>).</p><p>We applied the immunohistological stainings of cell cycle related markers on the residual samples available from the original IKA Tamoxifen study of 1662 patients. In the cohort of 394 patients which was available for the marker study, tumour recurrence was still associated with the base-line clinical prognostic parameters such as grade, stage and lymph node involvement, as was the case in the original study including 1662 patients, indicating that the sample used for the present study was representative (<xref ref-type="other" rid="bib45">Vermorken <italic>et al</italic>, 1998</xref>). A drawback of this study was the relatively short period of tamoxifen treatment of the patients during 1 or 3 years, according to the original setting up of the trial. Recent studies suggest that tamoxifen should be given for longer periods (probably 5 years or more) (<xref ref-type="other" rid="bib15">Early Breast Cancer Trialist's Collaborative Group, 1998</xref>; <xref ref-type="other" rid="bib17">Fischer <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib43">Steward <italic>et al</italic>, 2001</xref>). In our marker study about 50&#x00025; of the patients received tamoxifen for only 1 year and 74 patients did not receive tamoxifen treatment at all. This shorter period of tamoxifen treatment has most likely influenced our results in narrowing the effective window of tamoxifen treatment. Nevertheless, some putative prognostic indicators for treatment could be identified in this group of tamoxifen-treated patients.</p><p>Overexpression of cyclin D1 is generally found in OR-&#x003b1;-positive, more differentiated breast cancer (<xref ref-type="other" rid="bib21">Gillett <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib27">Michalides <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib44">Van Diest <italic>et al</italic>, 1997</xref>), whereas overexpression of cyclin A is associated with OR-&#x003b1;-negative, undifferentiated breast cancer (this study). In both cases overexpression of the cyclins is associated with higher proliferation index (Ki-67 staining). The effect of overexpression of cyclin D1 on the outcome of tamoxifen treatment is controversial: overexpression of cyclin D1 messenger RNA was found to be predictive of poor prognosis in lymph node positive, OR-&#x003b1;-positive breast cancer (<xref ref-type="other" rid="bib24">Kenny <italic>et al</italic>, 1999</xref>), which would support the hypothesis raised above. However, other reports indicate that moderate/strong staining of cyclin D1 protein was associated with complete or partial response to tamoxifen treatment (<xref ref-type="other" rid="bib17">Fischer <italic>et al</italic>, 2001</xref>). Our study shows no effect of cyclin D1, neither on the incidence of recurrence, as was also reported previously (<xref ref-type="other" rid="bib27">Michalides <italic>et al</italic>, 1996</xref>), nor on outcome of tamoxifen treatment within the OR-&#x003b1;-positive group of patients. Since cyclin D1 staining is associated with OR positivity, overexpression of cyclin D1 is likely indicating a beneficial response to tamoxifen when all breast cancers, OR-positive and -negative, are taken together.</p><p>Overexpression of cyclin A is associated with undifferentiated, OR-negative and Ki-67 positive breast tumours, which are general features of a more aggressive breast tumour phenotype. Overexpression of cyclin A protein may represent an increased growth fraction of the tumour, an elevated expression of cyclin A protein per tumour cell, or a combination of both. The end result, increased positivity of a tumour for cyclin A staining, is associated with poor clinical course. Since cyclin A associated kinase activity is stimulated by cdc25A, the effect of overexpression of cyclin may well be redundant with that of cdc25A (<xref ref-type="other" rid="bib5">Blomberg and Hoffmann, 1999</xref>). Interestingly, overexpression of cdc25A is indicative of a weakly increased risk of dying of disease (<xref ref-type="other" rid="bib9">Cangi <italic>et al</italic>, 2000</xref>), whereas cyclin A is a significant prognostic indicator of poor prognosis, for OR-positive as well as for OR-negative breast cancer (<xref ref-type="other" rid="bib8">Bukholm <italic>et al</italic>, 2001</xref>; this study).</p><p>These results and those of others (<xref ref-type="other" rid="bib30">Nielsen <italic>et al</italic>, 1999</xref>) indicate that defects in G1 regulation are involved in breast cancer progression, and that particular defects are indicative of prognosis and of response to tamoxifen therapy. The relatively weak statistical significance of these associations with prognosis suggests, however, that other interactive factors are involved. This study and that of <xref ref-type="other" rid="bib9">Cangi <italic>et al</italic> (2000)</xref> provide evidence that the anti-mitogenic effects of anti-oestrogens are also <italic>in vivo</italic> to be overcome by mechanisms that affect cdk2 activation and cyclin A expression. Patients with such a primary breast cancer may therefore, benefit from other treatments, for instance from chemotherapy or potential cdk2 inhibitors. We found that cyclin A overexpression is indicative of a poor prognosis in early stage breast cancer and may therefore, serve to further differentiate therapy in both tamoxifen-treated and non-treated patients.</p></sec></body><back><ack><p>We would like to acknowledge A&#x000ef;cha Ridouan, Nalini Radjkoemar, Kitty Nora de Vries, K de Goeij and M Tjin-A-Koeng for assistance with immunohistochemistry, and J Peterse (Dept. of Pathology, the Netherlands Cancer Institute, Amsterdam) for reviewing part of the tumour samples. This project was supported by the Dutch Cancer Society grant no 97-1431 and by a grant from IKA.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altucci</surname><given-names>L</given-names></name><name><surname>Addeo</surname><given-names>R</given-names></name><name><surname>Cicatiello</surname><given-names>L</given-names></name><name><surname>Dauvois</surname><given-names>S</given-names></name><name><surname>Parker</surname><given-names>MG</given-names></name><name><surname>Truss</surname><given-names>M</given-names></name><name><surname>Beato</surname><given-names>M</given-names></name><name><surname>Sica</surname><given-names>V</given-names></name><name><surname>Bresciani</surname><given-names>F</given-names></name><name><surname>Weisz</surname><given-names>A</given-names></name></person-group><article-title>17&#x003b2;-estradiol induces cyclin D1 gene transcription, p36<sup>D1</sup>-p34<sup>cdk4</sup> complex activation and p105Rb phosphorylation during mitogenic stimulation of G1 arrested human breast cancer cells</article-title><source>Oncogene</source><year>1996</year><volume>12</volume><fpage>2315</fpage><lpage>2324</lpage><!--PubMed citation query: 'Oncogene||12|2315||bib1|'--><pub-id pub-id-type="pmid">8649771</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berns</surname><given-names>EM</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Vossen</surname><given-names>R</given-names></name><name><surname>Look</surname><given-names>MP</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Henzen-Logmans</surname><given-names>SC</given-names></name><name><surname>van Klaveren</surname><given-names>IL</given-names></name><name><surname>van Putten</surname><given-names>WL</given-names></name><name><surname>Inganas</surname><given-names>M</given-names></name><name><surname>Meijer-van Gelder</surname><given-names>ME</given-names></name><name><surname>Cornelisse</surname><given-names>C</given-names></name><name><surname>Claassen</surname><given-names>CJ</given-names></name><name><surname>Portengen</surname><given-names>H</given-names></name><name><surname>Bakker</surname><given-names>B</given-names></name><name><surname>Klijn</surname><given-names>JG</given-names></name></person-group><article-title>Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>2155</fpage><lpage>2162</lpage><!--PubMed citation query: 'Cancer Res||60|2155||bib2|'--><pub-id pub-id-type="pmid">10786679</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbareschi</surname><given-names>M</given-names></name><name><surname>Pelosio</surname><given-names>P</given-names></name><name><surname>Caffo</surname><given-names>O</given-names></name><name><surname>Buttitta</surname><given-names>F</given-names></name><name><surname>Pellegrini</surname><given-names>S</given-names></name><name><surname>Barbaza</surname><given-names>R</given-names></name><name><surname>Dalla Palma</surname><given-names>P</given-names></name><name><surname>Bevilacqua</surname><given-names>G</given-names></name><name><surname>Marchetti</surname><given-names>A</given-names></name></person-group><article-title>Cyclin D1 gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21(WAF1) immunohistochemical expression</article-title><source>Int J Cancer</source><year>1997</year><volume>74</volume><fpage>171</fpage><lpage>174</lpage><!--PubMed citation query: 'Int J Cancer||74|171||bib3|'--><pub-id pub-id-type="pmid">9133450</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbareschi</surname><given-names>M</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Mauri</surname><given-names>FA</given-names></name><name><surname>Veronese</surname><given-names>S</given-names></name><name><surname>Peterse</surname><given-names>H</given-names></name><name><surname>Maissonneuve</surname><given-names>P</given-names></name><name><surname>Caffo</surname><given-names>O</given-names></name><name><surname>Scaioli</surname><given-names>M</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name><name><surname>Galligioni</surname><given-names>E</given-names></name><name><surname>Dalla Parma</surname><given-names>P</given-names></name><name><surname>Michalides</surname><given-names>R</given-names></name></person-group><article-title>p27<sup>Kip1</sup> expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up</article-title><source>Int J Cancer (Pred Onc)</source><year>2000</year><volume>89</volume><fpage>236</fpage><lpage>241</lpage><!--PubMed citation query: 'Int J Cancer (Pred Onc)||89|236||bib4|'--></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blomberg</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>I</given-names></name></person-group><article-title>Ectopic expression of cdc25A accelerates the G1/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases</article-title><source>Mol Cell Biol</source><year>1999</year><volume>19</volume><fpage>6138</fpage><lpage>6194</lpage><!--PubMed citation query: 'Mol Cell Biol||19|6138||bib5|'--></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bodrug</surname><given-names>SE</given-names></name><name><surname>Warner</surname><given-names>BJ</given-names></name><name><surname>Bath</surname><given-names>ML</given-names></name><name><surname>Lindemans</surname><given-names>GL</given-names></name><name><surname>Harris</surname><given-names>AW</given-names></name><name><surname>Adams</surname><given-names>JM</given-names></name></person-group><article-title>Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene</article-title><source>EMBO J</source><year>1994</year><volume>13</volume><fpage>2124</fpage><lpage>2130</lpage><!--PubMed citation query: 'EMBO J||13|2124||bib6|'--><pub-id pub-id-type="pmid">8187765</pub-id></citation></ref><ref id="bib7"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Fuqua</surname><given-names>S</given-names></name><name><surname>Allred</surname><given-names>C</given-names></name></person-group><article-title>Pathogenesis of estrogen-receptor positive and -negative breast cancer</article-title><source>Contemporary Endocrinology:Endocrine Oncology</source><year>1999</year><publisher-name>Totowa, NJ: Humana Press Inc</publisher-name><fpage>49</fpage><lpage>68</lpage>Ethier SP (ed.)pp&#x02009;</citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bukholm</surname><given-names>IR</given-names></name><name><surname>Bukholm</surname><given-names>G</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name></person-group><article-title>Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast cancer</article-title><source>Int J Cancer</source><year>2001</year><volume>15</volume><fpage>283</fpage><lpage>287</lpage><!--PubMed citation query: 'Int J Cancer||15|283||bib8|'--></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cangi</surname><given-names>MG</given-names></name><name><surname>Cukor</surname><given-names>B</given-names></name><name><surname>Soyung</surname><given-names>P</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Moreira</surname><given-names>G</given-names></name><name><surname>Ranasingheb</surname><given-names>M</given-names></name><name><surname>Cady</surname><given-names>B</given-names></name><name><surname>Pagano</surname><given-names>M</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name></person-group><article-title>Role of the Cdc25A phosphatase in human breast cancer</article-title><source>J Clin Inv</source><year>2000</year><volume>106</volume><fpage>753</fpage><lpage>761</lpage><!--PubMed citation query: 'J Clin Inv||106|753||bib9|'--></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cariou</surname><given-names>S</given-names></name><name><surname>Donovan</surname><given-names>JCH</given-names></name><name><surname>Flanagan</surname><given-names>WM</given-names></name><name><surname>Milic</surname><given-names>A</given-names></name><name><surname>Bhattachatya</surname><given-names>N</given-names></name><name><surname>Slingerland</surname><given-names>JM</given-names></name></person-group><article-title>Down-regulation of p21<sup>WAF/CIP1</sup> or p27<sup>Kip1</sup> abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>9042</fpage><lpage>9046</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||97|9042||bib10|'--></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chalbos</surname><given-names>D</given-names></name><name><surname>Vignon</surname><given-names>F</given-names></name><name><surname>Keydar</surname><given-names>I</given-names></name><name><surname>Rochefort</surname><given-names>H</given-names></name></person-group><article-title>Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D)</article-title><source>J Clin Endocrine Metab</source><year>1982</year><volume>55</volume><fpage>276</fpage><lpage>283</lpage><!--PubMed citation query: 'J Clin Endocrine Metab||55|276||bib11|'--></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cicatiello</surname><given-names>L</given-names></name><name><surname>Addeo</surname><given-names>R</given-names></name><name><surname>Altucci</surname><given-names>L</given-names></name><name><surname>Petrizzi</surname><given-names>VB</given-names></name><name><surname>Boccia</surname><given-names>V</given-names></name><name><surname>Cancemi</surname><given-names>M</given-names></name><name><surname>Germano</surname><given-names>D</given-names></name><name><surname>Pacilio</surname><given-names>C</given-names></name><name><surname>Salzano</surname><given-names>S</given-names></name><name><surname>Bresciani</surname><given-names>F</given-names></name><name><surname>Weisz</surname><given-names>A</given-names></name></person-group><article-title>The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion</article-title><source>Mol Cell Endocrinol</source><year>2000</year><volume>165</volume><fpage>199</fpage><lpage>209</lpage><!--PubMed citation query: 'Mol Cell Endocrinol||165|199||bib12|'--><pub-id pub-id-type="pmid">10940498</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Jong</surname><given-names>JS</given-names></name><name><surname>van Diest</surname><given-names>PJ</given-names></name><name><surname>Michalides</surname><given-names>RJAM</given-names></name><name><surname>Baak</surname><given-names>JPA</given-names></name></person-group><article-title>Concerted overexpression of the genes encoding p21 and cyclin D1 is associated with growth inhibition and differentiation in various carcinomas</article-title><source>Mol Pathol</source><year>1999</year><volume>52</volume><fpage>78</fpage><lpage>83</lpage><!--PubMed citation query: 'Mol Pathol||52|78||bib13|'--><pub-id pub-id-type="pmid">10474686</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>JA</given-names></name><name><surname>Zindy</surname><given-names>F</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitine-proteasome pathway</article-title><source>Genes Dev</source><year>1997</year><volume>11</volume><fpage>957</fpage><lpage>971</lpage><!--PubMed citation query: 'Genes Dev||11|957||bib14|'--><pub-id pub-id-type="pmid">9136925</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><collab>Early Breast Cancer Trialist's Collaborative Group</collab></person-group><article-title>Tamoxifen for early breast cancer: an overview of randomised trials</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1451</fpage><lpage>1467</lpage><!--PubMed citation query: 'Lancet||351|1451||bib15|'--><pub-id pub-id-type="pmid">9605801</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elston</surname><given-names>CW</given-names></name><name><surname>Ellis</surname><given-names>OI</given-names></name></person-group><article-title>Pathology and breast cancer screening</article-title><source>Histopathology</source><year>1990</year><volume>16</volume><fpage>109</fpage><lpage>118</lpage><!--PubMed citation query: 'Histopathology||16|109||bib16|'--><pub-id pub-id-type="pmid">2182506</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Dignam</surname><given-names>J</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><article-title>Five versus more than five years of tamoxifen for lymph-node negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><fpage>684</fpage><lpage>690</lpage><!--PubMed citation query: 'J Natl Cancer Inst||93|684||bib17|'--><pub-id pub-id-type="pmid">11333290</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>JS</given-names></name><name><surname>Wimalasena</surname><given-names>J</given-names></name></person-group><article-title>Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells</article-title><source>Mol Endocrinol</source><year>1996</year><volume>10</volume><fpage>488</fpage><lpage>498</lpage><!--PubMed citation query: 'Mol Endocrinol||10|488||bib18|'--><pub-id pub-id-type="pmid">8732680</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>JS</given-names></name><name><surname>Henley</surname><given-names>DC</given-names></name><name><surname>Bukovsky</surname><given-names>A</given-names></name><name><surname>Seth</surname><given-names>P</given-names></name><name><surname>Wimalasena</surname><given-names>J</given-names></name></person-group><article-title>Multifaceted regulation of cell cycle progression by estrogen: regulation of cdk inhibitors and Cdc25A independent of cyclin D1-cdk4 function</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>794</fpage><lpage>810</lpage><!--PubMed citation query: 'Mol Cell Biol||21|794||bib19|'--><pub-id pub-id-type="pmid">11154267</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galaktionov</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>AK</given-names></name><name><surname>Echstein</surname><given-names>G</given-names></name><name><surname>Draetta</surname><given-names>J</given-names></name><name><surname>Meckler</surname><given-names>J</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Beach</surname><given-names>D</given-names></name></person-group><article-title>Cdc25 phosphatases as potential human oncogenes</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>1575</fpage><lpage>1577</lpage><!--PubMed citation query: 'Science||269|1575||bib20|'--><pub-id pub-id-type="pmid">7667636</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Gregory</surname><given-names>W</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Millis</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>G</given-names></name><name><surname>Barnes</surname><given-names>D</given-names></name></person-group><article-title>Cyclin D1 and prognosis</article-title><source>Int J Cancer (Pred Onc)</source><year>1996</year><volume>69</volume><fpage>92</fpage><lpage>99</lpage><!--PubMed citation query: 'Int J Cancer (Pred Onc)||69|92||bib21|'--></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Houston</surname><given-names>SJ</given-names></name><name><surname>Plunkett</surname><given-names>TA</given-names></name><name><surname>Barnes</surname><given-names>DM</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Rubens</surname><given-names>RD</given-names></name><name><surname>Miles</surname><given-names>DW</given-names></name></person-group><article-title>Overexpression of c-erBb2 is an independent marker of resistance to endocrine therapy in advanced breast cancer</article-title><source>Br J Cancer</source><year>1999</year><volume>79</volume><fpage>1220</fpage><lpage>1226</lpage><!--PubMed citation query: 'Br J Cancer||79|1220||bib22|'--><pub-id pub-id-type="pmid">10098763</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jinno</surname><given-names>SK</given-names></name><name><surname>Suto</surname><given-names>A</given-names></name><name><surname>Nagata</surname><given-names>M</given-names></name><name><surname>Igarashi</surname><given-names>M</given-names></name><name><surname>Kanaoka</surname><given-names>Y</given-names></name><name><surname>Nojima</surname><given-names>H</given-names></name><name><surname>Okayama</surname><given-names>H</given-names></name></person-group><article-title>Cdc25A is a novel phosphatase functioning early in the cell cycle</article-title><source>EMBO J</source><year>1994</year><volume>13</volume><fpage>1549</fpage><lpage>1556</lpage><!--PubMed citation query: 'EMBO J||13|1549||bib23|'--><pub-id pub-id-type="pmid">8156993</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>FS</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Mushgrove</surname><given-names>E</given-names></name><name><surname>Gee</surname><given-names>JMW</given-names></name><name><surname>Blamey</surname><given-names>RW</given-names></name><name><surname>Nicholson</surname><given-names>RI</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Robertson</surname><given-names>JFR</given-names></name></person-group><article-title>Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor -positive breast cancer</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>2069</fpage><lpage>2076</lpage><!--PubMed citation query: 'Clin Cancer Res||5|2069||bib24|'--><pub-id pub-id-type="pmid">10473088</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>J</given-names></name><name><surname>Ladha</surname><given-names>MH</given-names></name><name><surname>McMahon</surname><given-names>C</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name><name><surname>Ewen</surname><given-names>ME</given-names></name></person-group><article-title>Regulation between the functional interaction between cyclin D1 and the estrogen receptor</article-title><source>Mol Cell Biol</source><year>2000</year><volume>20</volume><fpage>8667</fpage><lpage>8675</lpage><!--PubMed citation query: 'Mol Cell Biol||20|8667||bib25|'--><pub-id pub-id-type="pmid">11073968</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>ACK</given-names></name><name><surname>Hanby</surname><given-names>AM</given-names></name><name><surname>Potts</surname><given-names>HWW</given-names></name><name><surname>Tan</surname><given-names>DSP</given-names></name><name><surname>Skilton</surname><given-names>D</given-names></name><name><surname>Ryder</surname><given-names>K</given-names></name><name><surname>Harris</surname><given-names>WH</given-names></name><name><surname>Liebmann</surname><given-names>RD</given-names></name><name><surname>Barnes</surname><given-names>DM</given-names></name><name><surname>Gillett</surname><given-names>CE</given-names></name></person-group><article-title>Cell cycle proteins do not predict outcome in grade 1 infiltrating ductal carcinoma of the breast</article-title><source>Int J Cancer (Pred Onc)</source><year>2000</year><volume>90</volume><fpage>26</fpage><lpage>31</lpage><!--PubMed citation query: 'Int J Cancer (Pred Onc)||90|26||bib26|'--></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michalides</surname><given-names>R</given-names></name><name><surname>Hageman</surname><given-names>P</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Houben</surname><given-names>L</given-names></name><name><surname>Wientjens</surname><given-names>E</given-names></name><name><surname>Klompmaker</surname><given-names>R</given-names></name><name><surname>Peterse</surname><given-names>J</given-names></name></person-group><article-title>A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer</article-title><source>Br J Cancer</source><year>1996</year><volume>73</volume><fpage>728</fpage><lpage>734</lpage><!--PubMed citation query: 'Br J Cancer||73|728||bib27|'--><pub-id pub-id-type="pmid">8611372</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michalides</surname><given-names>RJAM</given-names></name></person-group><article-title>Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer</article-title><source>J Clin Pathol</source><year>1999</year><volume>52</volume><fpage>555</fpage><lpage>568</lpage><!--PubMed citation query: 'J Clin Pathol||52|555||bib28|'--><pub-id pub-id-type="pmid">10645224</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Hamilton</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Sweeney</surname><given-names>KJE</given-names></name><name><surname>Watts</surname><given-names>CKW</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name></person-group><article-title>Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell progression</article-title><source>Mol Cell Biol</source><year>1993</year><volume>13</volume><fpage>3577</fpage><lpage>3587</lpage><!--PubMed citation query: 'Mol Cell Biol||13|3577||bib29|'--><pub-id pub-id-type="pmid">8497271</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>NH</given-names></name><name><surname>L&#x000f3;den</surname><given-names>M</given-names></name><name><surname>Cajander</surname><given-names>J</given-names></name><name><surname>Emdin</surname><given-names>SO</given-names></name><name><surname>Landberg</surname><given-names>G</given-names></name></person-group><article-title>G1-S transition defects occur in most breast cancers and predict outcome</article-title><source>Breast Cancer Res Treat</source><year>1999</year><volume>56</volume><fpage>105</fpage><lpage>112</lpage><!--PubMed citation query: 'Breast Cancer Res Treat||56|105||bib30|'--><pub-id pub-id-type="pmid">10573103</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osborne</surname><given-names>CK</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Fuqua</surname><given-names>SAW</given-names></name></person-group><article-title>Selective estrogen receptor modulators: structure, function, and clinical use</article-title><source>J Clin Onc</source><year>2000</year><volume>18</volume><fpage>3172</fpage><lpage>3186</lpage><!--PubMed citation query: 'J Clin Onc||18|3172||bib31|'--></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pacilio</surname><given-names>C</given-names></name><name><surname>Germano</surname><given-names>D</given-names></name><name><surname>Addeo</surname><given-names>R</given-names></name><name><surname>Altucci</surname><given-names>L</given-names></name><name><surname>Petrizzi</surname><given-names>VB</given-names></name><name><surname>Cancemi</surname><given-names>M</given-names></name><name><surname>Cicatiello</surname><given-names>L</given-names></name><name><surname>Salzano</surname><given-names>S</given-names></name><name><surname>Lallemand</surname><given-names>F</given-names></name><name><surname>Michalides</surname><given-names>RJAM</given-names></name><name><surname>Bresciani</surname><given-names>F</given-names></name><name><surname>Weisz</surname><given-names>A</given-names></name></person-group><article-title>Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>871</fpage><lpage>876</lpage><!--PubMed citation query: 'Cancer Res||58|871||bib32|'--><pub-id pub-id-type="pmid">9500441</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Planas-Silva</surname><given-names>MD</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution</article-title><source>Mol Cell Biol</source><year>1997</year><volume>17</volume><fpage>4059</fpage><lpage>4069</lpage><!--PubMed citation query: 'Mol Cell Biol||17|4059||bib33|'--><pub-id pub-id-type="pmid">9199341</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prall</surname><given-names>OW</given-names></name><name><surname>Sarcevic</surname><given-names>EA</given-names></name><name><surname>Musgrove</surname><given-names>EA</given-names></name><name><surname>Watts</surname><given-names>CKW</given-names></name><name><surname>Sutherland</surname><given-names>RL</given-names></name></person-group><article-title>Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>10882</fpage><lpage>10894</lpage><!--PubMed citation query: 'J Biol Chem||272|10882||bib34|'--><pub-id pub-id-type="pmid">9099745</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quelle</surname><given-names>DE</given-names></name><name><surname>Ashmun</surname><given-names>RA</given-names></name><name><surname>Shurtleff</surname><given-names>SE</given-names></name><name><surname>Kato</surname><given-names>JY</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Roussel</surname><given-names>M</given-names></name><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><article-title>Overexpression of mouse D-type cyclins accelerates G<sub>1</sub> phase in rodent fibroblasts</article-title><source>Genes Dev</source><year>1993</year><volume>7</volume><fpage>1559</fpage><lpage>1571</lpage><!--PubMed citation query: 'Genes Dev||7|1559||bib35|'--><pub-id pub-id-type="pmid">8339933</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ricketts</surname><given-names>D</given-names></name></person-group><article-title>Estrogen and progesterone receptors in normal female breast</article-title><source>Cancer Res</source><year>1991</year><volume>51</volume><fpage>1817</fpage><lpage>1822</lpage><!--PubMed citation query: 'Cancer Res||51|1817||bib36|'--><pub-id pub-id-type="pmid">2004366</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robles</surname><given-names>AI</given-names></name><name><surname>Larcher</surname><given-names>F</given-names></name><name><surname>Whalin</surname><given-names>RB</given-names></name><name><surname>Murillas</surname><given-names>R</given-names></name><name><surname>Richie</surname><given-names>E</given-names></name><name><surname>Gimenez-Conti</surname><given-names>I</given-names></name><name><surname>Jorcano</surname><given-names>JL</given-names></name><name><surname>Conti</surname><given-names>C</given-names></name></person-group><article-title>Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>7634</fpage><lpage>7638</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||93|7634||bib37|'--></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogatsky</surname><given-names>I</given-names></name><name><surname>Trowbridge</surname><given-names>JM</given-names></name><name><surname>Garabedian</surname><given-names>MJ</given-names></name></person-group><article-title>Potentiation of human estrogen receptor &#x003b1; transcriptional activation through phosphorylation of serines 104 and 106 by the cyclinA-cdk2 complex</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>22296</fpage><lpage>22302</lpage><!--PubMed citation query: 'J Biol Chem||274|22296||bib38|'--><pub-id pub-id-type="pmid">10428798</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabbah</surname><given-names>M</given-names></name><name><surname>Courilleau</surname><given-names>D</given-names></name><name><surname>Mester</surname><given-names>J</given-names></name><name><surname>Redeuilh</surname></name></person-group><article-title>Estrogen induction of cyclin D1 promoter: Involvement of a cAMP response-like element</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>11217</fpage><lpage>11222</lpage><!--PubMed citation query: 'Proc Natl Acad Sci USA||96|11217||bib39|'--></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name><name><surname>Roberts</surname><given-names>JM</given-names></name></person-group><article-title>CDK inhibitors: positive and negative regulators of G<sub>1</sub>-phase progression</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>1501</fpage><lpage>1512</lpage><!--PubMed citation query: 'Genes Dev||13|1501||bib40|'--><pub-id pub-id-type="pmid">10385618</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Wong</surname><given-names>SG</given-names></name><name><surname>Levin</surname><given-names>WJ</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>WL</given-names></name></person-group><article-title>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>177</fpage><lpage>182</lpage><!--PubMed citation query: 'Science||235|177||bib41|'--><pub-id pub-id-type="pmid">3798106</pub-id></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stal</surname><given-names>O</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Ferno</surname><given-names>M</given-names></name><name><surname>Kallstrom</surname><given-names>AC</given-names></name><name><surname>Malmstrom</surname><given-names>P</given-names></name><name><surname>Nordenskjold</surname><given-names>B</given-names></name></person-group><article-title>ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer</article-title><source>Ann Oncol</source><year>2000</year><volume>11</volume><fpage>1545</fpage><lpage>1550</lpage><!--PubMed citation query: 'Ann Oncol||11|1545||bib42|'--><pub-id pub-id-type="pmid">11205461</pub-id></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steward</surname><given-names>HJ</given-names></name><name><surname>Prescott</surname><given-names>RJ</given-names></name><name><surname>Forrest</surname><given-names>PM</given-names></name></person-group><article-title>Scottish Adjuvant Tamoxifen Trial: a randomized study updated to 15 years</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>36</volume><fpage>456</fpage><lpage>462</lpage><!--PubMed citation query: 'J Natl Cancer Inst||36|456||bib43|'--></citation></ref><ref id="bib44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Diest</surname><given-names>P</given-names></name><name><surname>Michalides</surname><given-names>RJAM</given-names></name><name><surname>Jannink</surname><given-names>I</given-names></name><name><surname>van der Valk</surname><given-names>P</given-names></name><name><surname>Peterse</surname><given-names>HL</given-names></name><name><surname>de Jong</surname><given-names>JS</given-names></name><name><surname>Meijer</surname><given-names>CJL</given-names></name><name><surname>Baak</surname><given-names>JPA</given-names></name></person-group><article-title>Cyclin D1 expression in invasive breast cancer, correlations and prognostic value</article-title><source>Am J Pathol</source><year>1997</year><volume>150</volume><fpage>705</fpage><lpage>711</lpage><!--PubMed citation query: 'Am J Pathol||150|705||bib44|'--><pub-id pub-id-type="pmid">9033283</pub-id></citation></ref><ref id="bib45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vermorken</surname><given-names>JB</given-names></name><name><surname>Burgers</surname><given-names>JMV</given-names></name><name><surname>Taat</surname><given-names>CW</given-names></name><name><surname>van de Slee</surname><given-names>PHT</given-names></name><name><surname>Hennipman</surname><given-names>A</given-names></name><name><surname>Norman</surname><given-names>JWR</given-names></name><name><surname>Roozendaal</surname><given-names>KJ</given-names></name><name><surname>van Tinteren</surname><given-names>H</given-names></name><name><surname>Huldij</surname><given-names>J</given-names></name><name><surname>Benraadt</surname><given-names>J</given-names></name></person-group><article-title>Adjuvant tamoxifen in breast cancer: interim results of a comprehensive cancer center Amsterdam trial</article-title><source>ASABCS</source><year>1998</year><volume>21</volume><fpage>329</fpage>(abstract)<!--PubMed citation query: 'ASABCS||21|329||bib45|'--></citation></ref><ref id="bib46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TC</given-names></name><name><surname>Cardiff</surname><given-names>RD</given-names></name><name><surname>Zukerberg</surname><given-names>L</given-names></name><name><surname>Lees</surname><given-names>E</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>EV</given-names></name></person-group><article-title>Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice</article-title><source>Nature</source><year>1994</year><volume>369</volume><fpage>669</fpage><lpage>671</lpage><!--PubMed citation query: 'Nature||369|669||bib46|'--><pub-id pub-id-type="pmid">8208295</pub-id></citation></ref><ref id="bib47"><citation citation-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title/><source>Histological Typing of Breast Tumours</source><year>1981</year><publisher-name>Geneva: World Health Organisation</publisher-name>2nd edn</citation></ref><ref id="bib48"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name></person-group><article-title>Tamoxifen and other antiestrogens in prevention and therapy of breast cancer</article-title><source>Contemporary Endocrinology:Endocrine Oncology</source><year>1999</year><publisher-name>Totowa, NJ: Humana Press Inc</publisher-name><fpage>79</fpage><lpage>100</lpage>Ethier SP (ed.)pp&#x02009;</citation></ref><ref id="bib49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zwijsen</surname><given-names>RLM</given-names></name><name><surname>Wientjens</surname><given-names>E</given-names></name><name><surname>Klompmaker</surname><given-names>R</given-names></name><name><surname>van der Sman</surname><given-names>J</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Michalides</surname><given-names>RJAM</given-names></name></person-group><article-title>Cdk-independent activation of estrogen receptor by cyclin D1</article-title><source>Cell</source><year>1997</year><volume>88</volume><fpage>405</fpage><lpage>415</lpage><!--PubMed citation query: 'Cell||88|405||bib49|'--><pub-id pub-id-type="pmid">9039267</pub-id></citation></ref><ref id="bib50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zwijsen</surname><given-names>RML</given-names></name><name><surname>Buckle</surname><given-names>RS</given-names></name><name><surname>Hijmans</surname><given-names>EM</given-names></name><name><surname>Loomans</surname><given-names>CJM</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><article-title>Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1</article-title><source>Genes Dev</source><year>1999</year><volume>12</volume><fpage>3488</fpage><lpage>3498</lpage><!--PubMed citation query: 'Genes Dev||12|3488||bib50|'--><pub-id pub-id-type="pmid">9832502</pub-id></citation></ref></ref-list><app-group><app id="app1"><title/><sec><title/><p>Participating hospitals in the IKA trial (CKTO 8209) were: Medisch Centrum Alkmaar, Alg. Chr. Ziekenhuis Eemland (Amersfoort), Academisch Medisch Centrum (Amsterdam), Antoni van Leeuwenhoek Ziekenhuis (Amsterdam), Onze Lieve Vrouwe Gasthuis (Amsterdam), Vrije Universiteit Medisch Centrum (Amsterdam), Rode Kruis Ziekenhuis (Beverwijk), Ziekenhuis Gooi Noord (Blaricum), Gemini Ziekenhuis (Den Helder), Deventer Ziekenhuis, Albert Schweitzer Ziekenhuis (Dordrecht), Kennemer Gasthuis (Haarlem), Streekziekenhuis Coevorden-Hardenberg (Hardenberg), Spaarne Ziekenhuis (Heemstede), Streekziekenhuis Midden-Twente (Hengelo), Ziekenhuis Hilversum, Westfries Gasthuis (Hoorn), IJsselmeerziekenhuizen (Lelystad), St. Antonius Ziekenhuis (Nieuwegein), Medisch Spectrum Twente, locatie Oldenzaal, Waterlandziekenhuis (Purmerend), Diakonessenhuis (Utrecht), Universitair Medisch Centrum Utrecht, Streekziekenhuis Koningin Beatrix (Winterswijk).</p></sec></app></app-group></back></article>


